

# The Buying Experience of the Future

**Bigtincan Holdings Limited (ASX:BTH)**Morgan Stanley Australia Summit 2022

**David Keane | Co-Founder and CEO** 

9 June 2022

# We are a global leader in sales enablement software

An established leader in a growing space with leading teams in North America and an emerging business in European & Asia Pacific markets.

- One of few providers offering all 3 core capabilities: content, training and coaching, engagement
- → Bigtincan's recent 1H FY22 results show the benefits of scale with growing efficiency, strong organic growth and a positive adjusted EBITDA of \$1.2m
- → Winner of multiple industry awards including recent Gold Medalist in the 2022 SoftwareReviews Sales Enablement Data Quadrant Buyers Guide Report

**About Bigtincan (ASX:BTH)** 

## Globally established and growing ASX-listed enterprise SaaS business

2k+

Customer deployments

**21** 

Global locations 1m+

Enterprise users

90+

Fortune 500 customers

Countries with users

\$112m

**Annualised Recurring** Revenue @ 1H FY22

### Scalable, efficient growth vs PcP

ARR<sup>1</sup>

\$112m

**132%** 

Revenue

\$45.9m

**142%** 

Adjusted<sup>2</sup> EBITDA

\$1.2m

**133%** 

**Net Retention Ratio** 

107%

**12%** 

ITV

\$741m

**198%** 

Cash<sup>3</sup>

\$45.4m

<sup>1</sup> Annualised Recurring Revenue (ARR) represents contracted, recurring revenue on an annualised basis. NB. All amounts are AUD.

<sup>2</sup> Adjusted EBITDA includes adjustments for acquisition, share based payments and one-off items. NB: See Glossary for all definitions

<sup>3</sup> Ending cash at 31 March 2022

Our mission

Engage Customers Create the Buying Experience of the Future

Empower Sellers


### The buying experience of the future




**Intelligent Enablement Platform** 

## A Portfolio of Expanding TAMs


Total Addressable Market Growth from FY22-FY26 has been expanded



## Key Investment Highlights











Large TAM impacting every buyer/seller interaction

Efficient growth engine

Attractive unit economics

Single platform based on a multi-Hub offering Demonstrated, repeatable growth

### **Growth Sources**

New customer wins

Expansion in key existing customers

Technology innovation


New products driving cross sell/ up sell

### Continued Focus on Operating Leverage


Benefits of scale as Operating Costs improved 17% as a % of Revenue (without capitalisation improved 12%). With:

S&M 49%, improved 5% from PcP

Effective engineering operations without capitalization results strong at 7% improved from PcP



#### **OPERATING LEVERAGE (\$'000s)**





### 2H FY22 Results Progression


Positive adjusted EBITDA result expected for FY22 Target of achieving cash flow breakeven in FY23

95% recurring revenue

Unit Economics continue to progress - operating leverage, LTV/CAC







Sensors

Collecting data

Signals

Converting data into insights

Action

Respond to insights with **automated** personalizations

**Looking Forward** 

### The Future of Engagement

**Automation** 

Human

Phone, Zoom, In-person

Digital

Surveys, Contact Forms, Clicks

Virtual


Virtual Sales Rooms & more


### **Video Content**

### **FY22 and Beyond**

# Future Growth Opportunities

Bigtincan covers end-to-end needs of sales enablement and buyer experience management






New geographic or vertical market expansion areas





# Bigtincan + Gore

**Chris Picarde | VP of Sales North America** 



#### **Overview**

### **About Gore**

Headquartered in Newark, Delaware; Gore is a global materials science company focused on discovery, product innovation based on fluoropolymer technology and manufacturing

#### It has three main divisions:

- Performance Solutions
- Fabrics
- Medical

www.gore.com

\$3.4b

11,500 associates

38 work sites

#### **Current Footprint**

## Gore + Bigtincan

#### **Gore Medical**

The division that manufactures vascular grafts, endovascular and interventional devices, and surgical meshes used by healthcare professionals to improve the lives of patients worldwide

### **Before Bigtincan**

- Technology silos in each division
- Content scattered across different repositories (Sharepoint, OneDrive, Dropbox, etc.)
- Content wasn't accessible from the CRM (Salesforce)
- Lacked interactive content, playbooks, AR / VR content

#### **Current Solution**

- → Bigtincan Content + Learning Hubs
- Single source of truth for all marketing and training content located across different systems
- → Access from mobile devices, offline
- → Salesforce integration delivers content and learning within the CRM

### **Expansion roadmap**



### **Learning Hub**

Field sales and partners/distributors 5,000-10,000 users



### **Bigtincan XR**

Create immersive augmented and virtual reality medical device product experiences

1,200 users



### **Engagement Hub**

Use engagement insights captured through MS
Teams integration to understand buyer interests and personalize interactions

5,000-10,000 users





#### **VoiceVibes**


Leaders use practice and Al-powered tone of voice feedback to improve their presentation skills

5,000-10,000 users









### FY22 Outlook & Scale

\$119m+

FY22 ARR <sup>1</sup>


\$109m+

FY22 Revenue 1, 2

**Customer Deployments** 

Global Team

### Annualised Recurring Revenue (\$m)



	FY19	FY20	FY21	FY22 (e)
ARR	\$23.4m	\$35.8m	\$53.1m	\$119m+



# Thank you

# Glossary

Term	Definition	
ARR	Annualised Recurring Revenue. This is the monthly recurring revenue times 12 with exchange rates fixed at time of additional or conversion to AUD.	
LTV	Lifetime value. ARR times Gross margin divided by the inverse of retention.	
CAC	Customer acquisition costs (60% of S&M and Acquisition costs).	
MRR Retention	The 12-month trailing churn dollar total subtracted from the ending MRR dollar position divided by the ending dollar MRR position. This excludes acquisitions.	
Net Retention Ratio	(Beginning ARR + expansions + upsells - Churn - Contractions)/ Beginning ARR	
CAGR	Compound Annual Growth Rate	
PcP	Prior Corresponding Period	
TCV	Total Contract Value	
RPO	RPO is a SaaS metric that takes into account deferred revenue and adds the value of non-cancelable revenue that has yet to be billed but represents future performance obligations that will be earned as revenue.	

### Important Notice and Disclaimer

This presentation is provided by Bigtincan Holdings Limited ACN 154 944 797 (Bigtincan) to provide summary information about Bigtincan and its subsidiaries (the Group). Statements in this presentation are made only as at 9 June 2022 and the information in this presentation remains subject to change without notice. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes and should not be relied upon by the recipient.

This presentation is not, and does not constitute, or form any part of, an offer to sell or issue, or the solicitation, invitation or recommendation to purchase any securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation does not purport to summarise all information that a recipient should consider when making an investment decision, and should not form the basis of any decision by a recipient.

Recipients should carry out their own investigations and analysis of the Group and verify the accuracy, reliability and completeness of the information contained in this presentation or any other form of communication to which the recipient is permitted access in the course of evaluating an investment in Bigtincan.

#### No liability

To the maximum extent permitted by law, none of Bigtincan or its respective affiliates or related bodies corporate or any of their respective officers, directors, employees and agents (Related Parties), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, Bigtincan, the Group or Bigtincan securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released in the United States. Securities may not be offered or sold in the United States unless such securities are registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws. Any public offering of securities in the United States would be made by means of a prospectus that would be obtained from the issuer or selling security holder and that would contain detailed information regarding the company and management, as well as financial statements. Each institution or person that reviews this presentation will be deemed to represent that each such institution or person is not in the United States.

The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

#### Not financial product advice

Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not a financial product or investment advice or recommendation to acquire Bigtincan securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

You should make your own assessment of an investment in Bigtincan and should not rely on this presentation. In all cases, you should conduct your own research of Bigtincan and the Group and analysis of the financial condition, assets and liabilities. financial position and performance, profits and losses, prospects and business affairs of Biotincan, the Group and its business. and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

#### Past performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

#### **Future performance**

This presentation contains certain forward-looking statements with respect to the financial condition, operations and business of the Group and certain plans and objectives of the management of Bigtincan. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms "believes", "estimates", "anticipates", "expects, "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "quidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of the Group to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the political and economic environment in which the Group will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.

Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, Bigtincan, the Lead Manager and their respective affiliates and related bodies corporate and each of their respective Related Parties and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

#### Financial data

All figures in the presentation are A\$ unless stated otherwise.

#### **Financial Information**

Any pro forma and forecast financial information provided in this presentation is for illustrative purposes only and do not represent a forecast or expectation as to the Group's future financial condition and/or performance. This document has been prepared at a time where the review of financial information contained in this presentation has not been completed and accordingly, you should only rely on any forecast or expectation as to the Group's future financial condition and/or performance that is contained in a prospectus or other offering document which may be issued by Bigtincan in connection with any offer of Bigtincan securities.